Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
28 hedge funds and large institutions have $5.55M invested in Regulus Therapeutics in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
4% more funds holding
Funds holding: 27 → 28 (+1)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.71% less ownership
Funds ownership: 4.41% → 3.7% (-0.71%)
51% less capital invested
Capital invested by funds: $11.3M → $5.55M (-$5.78M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$48.7K |
| 2 |
VF
Virtu Financial
New York
|
+$13.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.7K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$6.34K |
| 5 |
Rockefeller Capital Management
New York
|
+$5.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.13M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$568K |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$50.5K |
| 4 |
Jane Street
New York
|
-$41K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$20K |
RGLS Hedge Fund Activity: Q3 2019 in Review
28 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2019, worth a combined $5.55M — down 51% from $11.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RGLS positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $48.7K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $1.13M sold.
- 28 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2019, up from 27 in Q2 2019.
- Funds reported $5.55M of Regulus Therapeutics stock for Q3 2019, down 51% quarter-over-quarter.
- 7 funds opened new Regulus Therapeutics positions in Q3 2019 and 6 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q3 2019 was Renaissance Technologies, an estimated $48.7K added.
- The largest Regulus Therapeutics seller in Q3 2019 was Samsara BioCapital, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2019.